# Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes

> **NCT01923181** · PHASE2 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 632 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** semaglutide
- **DRUG:** semaglutide
- **DRUG:** oral placebo

## Key facts

- **NCT ID:** NCT01923181
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12-02
- **Primary completion:** 2014-12-11
- **Final completion:** 2014-12-11
- **Target enrollment:** 632 (ACTUAL)
- **Last updated:** 2021-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01923181

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01923181, "Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01923181. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*